Brenda Kelly is about to greet her first class of Saints as president of the College of St. Scholastica. She joined The Lift ...
Secondary endpoints, including improvement in New York Heart Association functional class, a comprehensive exercise metric (Z ...
For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...
Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCMNew ...
ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both ...
Cytokinetics, Incorporated ( CYTK ), a biopharmaceutical company focused on developing muscle-directed therapies, announced positive results from its pivotal Phase 3 ACACIA-HCM trial of aficamten in ...
Cytokinetics (NASDAQ:CYTK) presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients ...
Opinion
The Military Show on MSNOpinion
Ukraine's massive satellite breakthrough… now Russia can never win
Ukraine is deploying the Dutch-supported Bravo1Alpha Close Satellite Support (CSS) system—dubbed the "God's Eye"—to stream near real-time commercial satellite imagery directly to frontline operators.
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with ...
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with ...
Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...
Key takeawaysThere are currently no approved treatments for symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The ACACIA-HCM trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results